Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-2505 in Major Depressive Disorder
NCT06236880Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2 trial of bretisilocin in major depressive disorder (MDD) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and Tolerability at 99 Days and Montgomery-Åsberg Depression Rating Scale at 29 Days. Started Jan 2024; status: completed.
02
Drugs
bretisilocin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06236880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236880.